Bayer Loses Yaz Patent in Federal Court of Appeals: Generic Yaz Versions Begin (Stealing) Marketshare
Bayer was recently dealt a setback in a Federal Court of Appeals in Washington. Their patent on Yaz, a contraceptive pill, was deemed to no longer be worthy of patent protection. Bayer’s patent on Yaz expires in June 2014. As a result of this ruling, Actavis Inc. and Novartis AG can sell generic versions of the birth control pill. Though the ruling now gives other pharmaceutical companies the ability to legally compete against Bayer in the drospirenone contraceptive pill market, generic and inexpensive versions of Yaz-like drugs are driving Continue Reading
Yaz Gallbladder Lawsuit Update: Bayer Settles Gallbladder Injury Yaz and Yasmin Lawsuits for $24 Million
Submit Your Claim A settlement agreement has been reached between Bayer and plaintiffs who filed a Yaz and Yasmin lawsuit specifically citing gallbladder complications. The settlement agreement between the plaintiffs and Bayer, the German pharmaceutical company responsible for the development and marketing of Yaz and Yasmin, was reached on March 15. The plaintiffs’ Yaz gallbladder lawsuits against Bayer were filed in courts across the U.S., including a Yaz and Yasmin multi-district litigation (MDL) in the U.S. District Court for the Southern District of Illinois. The Yaz and Yasmin MDL Continue Reading
Bayer Allocates $1.5 Billion as a Yaz and Yasmin Legal Fund: Settlement Agreements Reached in Yaz and Yasmin Lawsuits
Submit Your Claim According to a Reuters report published on March 4, Bayer allocated $1.5 billion last year as a legal fund for Yaz and Yasmin lawsuits. In anticipation of future settlements of Yaz and Yasmin lawsuits, Bayer has set these funds aside, as it faces thousands more lawsuits. Bayer recently reached a settlement agreement of $1 billion in 4,800 lawsuits filed against them in the U.S. These nearly 5,000 lawsuits were filed against the German pharmaceutical company because, as the plaintiffs claim, ingestion of the contraceptives Yaz and Continue Reading
Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation
Published October 12, 2012 by LawsuitInformation.org In recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals. In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led Continue Reading
Bayer 2012 Profits Impacted by Yaz and Yasmin Lawsuits
Published August 23, 2012 on LawsuitInformation.org It has been reported that Bayer, the German pharmaceutical giant responsible for the development of Yaz and Yasmin, the health threatening birth control pills of ill repute, has created what is essentially a savings account in the amount of 500 million euros for the purpose of future Yaz and Yasmin lawsuits. In a study conducted by the U.S. Food and Drug Administration (FDA) of Yaz and Yasmin, the FDA uncovered the high risk of blood clot development and a number of other serious Continue Reading
Yaz/Yasmin DVT & Pulmonary Embolism Settlements Progressing
Published July 10, 2012 by LawsuintInformation As a Yaz Pulmonary Embolism, Deep Vein Thrombosis Attorney I have written extensively about the risks inherent in birth control pills containing Drospirenone. According to status report held on June 22, in the U.S. District Court for the Southern District of Illinois, Bayer has reached agreements with about 33 different law firms to resolve at least 1,444 Yaz Deep Vein Thrombosis, Stroke and Pulmonary Embolism claims. According to Bloomberg News, as of late April, Bayer faced 11,900 lawsuits over Yaz and its sister Continue Reading
Controversy Surrounds the FDA’s Decision to Keep Yaz On the Market
Published June 20, 2012 on LawsuitInformation.org The FDA recently mandated that Bayer Pharmaceuticals change the warning labels on two of its most popular birth control pills to reflect recent research relating to blood clots as a result of Yasmin or Yaz. The decision comes in the midst of many ongoing lawsuits against Bayer and generic Yasmin or Yaz manufacturers relating to side effects resulting from Yaz, and has been met with criticism from watchdog groups and other advocacy groups accusing the FDA of not doing enough. FDA addresses concerns Continue Reading
Update June 2012: Yaz & Yasmin Court Information
Published June 21, 2012 on LawsuitInformation.org Yaz Lawsuit Court Info (6/13/12) — Seedol The latest addition to Yaz Lawsuit news is that attorneys are still taking cases for those whose health was severely affected through the use of this birth control. Yaz, Yasmin and other drospirenone-containing birth controls have been linked to devastating blood clots that can cause young victims to be on blood-thinning medication for the remainder of their lives. Many Yaz Lawsuits have been pursued for blood-clot related issues like a stroke, pulmonary embolism or deep vein Continue Reading
Effects of the Mensing Ruling on Yaz & Yasmin Lawsuits
Published June 4, 2012 on LawsuitInformation.org Yaz Lawsuit and The Mensing Ruling The Mensing Ruling refers to a ruling by the Supreme Court in the case of Pliva, Inc., et al. v. Mensing which essentially protected generic manufacturers from lawsuits for failure to warn about any side effects of their products beyond the warnings contained on the warning label of the name Brand product of which they are a “copy”. The ruling does not effect the Yaz Lawsuit or the Yazmin Lawsuit however, it may effect women who took Continue Reading
Yaz Lawsuit News Update
Published May 18, 2012 on Seedol Yaz Lawsuit News 05/18/2012: The extension of time to settle Yaz Lawsuits in the Multi District Litigation by the presiding Judge coupled with Bayer releasing information that they intend to settle Yaz Lawsuits without going to trial when possible has led to law firms accepting new clients for the Yaz Lawsuits. Many Law Firms were wrapping up their Yaz Case Docket in preparation for trial or settlement. Now that Bayer has been given an extension of time the Plaintiff Law Firms representing clients Continue Reading
